BAUSCH HEALTH AMERICAS, INC.
Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Matching placebo rectal foam
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05976802
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
- Conditions
- Hepatic Encephalopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 466
- Registration Number
- NCT05297448
- Locations
- 🇺🇸
Bausch Site 591, Homewood, Alabama, United States
🇺🇸Bausch Site 445, Chandler, Arizona, United States
🇺🇸Bausch Site 453, Sun City, Arizona, United States
Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: 50 mg/mL Virazole Inhalant ProductDrug: 100 mg/mL Virazole Inhalant ProductDrug: Placebo
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05229510
- Locations
- 🇨🇦
Bausch Site 1, Mississauga, Ontario, Canada
Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity
- Conditions
- Psoriasis
- Interventions
- Biological: Matched cohort
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 394
- Registration Number
- NCT05132231
- Locations
- 🇨🇦
CARE Site 52, Saint-Charles-Borromée, Quebec, Canada
🇨🇦CARE Site 42, Calgary, Alberta, Canada
🇨🇦CARE Site 26, Calgary, Alberta, Canada
Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease
- Conditions
- Sickle Cell Disease
- Interventions
- Drug: High Dose Rifaximin ERDrug: Low Dose Rifaximin ERDrug: Low Dose Rifaximin DERDrug: PlaceboDrug: High Dose Rifaximin DER
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05098028
- Locations
- 🇺🇸
Bausch Site 105, Orange, California, United States
🇺🇸Bausch Site 103, Denver, Colorado, United States
🇺🇸Bausch Site 104, Atlanta, Georgia, United States
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
- Conditions
- Hepatic Encephalopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 524
- Registration Number
- NCT05071716
- Locations
- 🇺🇸
Bausch Site 182, Dothan, Alabama, United States
🇺🇸Bausch Site 129, Chandler, Arizona, United States
🇺🇸Bausch Site 103, Peoria, Arizona, United States
Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment
- Conditions
- Photoaging
- Interventions
- Device: CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces.
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05027282
- Locations
- 🇺🇸
Bausch Site 001, Dallas, Texas, United States
Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 686
- Registration Number
- NCT04892706
- Locations
- 🇺🇸
Bausch Site 134, Bryant, Arkansas, United States
🇺🇸Bausch Site 118, Rogers, Arkansas, United States
🇺🇸Bausch Site 110, Fremont, California, United States
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: PlaceboDrug: High Dose MT-1303Drug: Low Dose MT-1303
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT04857112
- Locations
- 🇺🇸
Bausch Site 025, Chandler, Arizona, United States
🇺🇸Bausch Site 023, Tucson, Arizona, United States
🇺🇸Salix Site 004, Los Angeles, California, United States
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19
- Conditions
- COVID19
- Interventions
- Drug: 50 mg/mL VirazoleDrug: 100 mg/mL Virazole
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT04551768
- Locations
- 🇬🇷
Bausch Health Site 201, Athens, Attika, Greece
🇬🇷Bausch Health Site 203, Athens, Attika, Greece
🇬🇷Bausch Health Site 204, Alexandroupoli, Evros, Greece